Trial reportAnnals of the rheumatic diseases2014
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
Trial report in Annals of the rheumatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02825212 (Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.The Cochrane database of systematic reviews · 2018Pooled it
- Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.The Cochrane database of systematic reviews · 2014Pooled it
- Review
- A comparative study of different antiviral treatment protocols in HCV related cryoglobulinemic vasculitis.Scientific reports · 2024Article
- Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.Advances in experimental medicine and biology · 2021Review
- TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response.Inflammation · 2019Article
- Toll-Like Receptor 3-TRIF Pathway Activation byInfection and immunity · 2019Article
- Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience.Infection and drug resistance · 2018Article
- Review
- Gastrointestinal aspects of vasculitides.Nature reviews. Gastroenterology & hepatology · 2017Review
- Managing refractory cryoglobulinemic vasculitis: challenges and solutions.Journal of inflammation research · 2017Review
- Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy.Journal of clinical and translational hepatology · 2016Review
- The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.Clinical and experimental medicine · 2016Review
- Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.Hepatology (Baltimore, Md.) · 2016Article
- New approaches in the treatment of hepatitis C.World journal of gastroenterology · 2016Review
- Vasculitic Neuropathies.Current treatment options in neurology · 2015Article
- Dermatologic Extrahepatic Manifestations of Hepatitis C.Journal of clinical and translational hepatology · 2015Review
- Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver Cirrhosis.International journal of molecular sciences · 2015Article
- Management of patients with hepatitis C infection and renal disease.World journal of hepatology · 2015Review
- For patients with rheumatic disease and hepatitis C infection: the end of interferon.RMD open · 2015Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
16 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination.
objectiveTo analyse the safety and efficacy of Peg-IFNα/ribavirin/protease inhibitor combination in HCV-MC vasculitis. PATIENTS AND
methodsOpen-label, prospective, cohort study including 23 patients with HCV-MC vasculitis. Peg-IFNα/ribavirin was associated to telaprevir (375 mg three times daily, for 12 weeks, (n=15)) or boceprevir (800 mg three times daily, for 44 weeks, (n=8)) for 48 weeks.
resultsThe median age was 59 (52.5-66) years, with 48.8% women. Thirteen patients (56.5%) were complete clinical responders, and 10 (43.5%) were partial responders at week 24. The virological response (ie, HCV RNA negativation) was of 69.6% at week 24 (p=0.005). The cryoglobulin level decreased from 0.44 to 0.06 g/l (p=0.0006) and the C4 level increased from 0.09 to 0.15 g/l (p=0.045). Grades 3 and 4 adverse events (mainly anaemia, neutropenia and thrombocytopenia) were observed in 10 cases (43.5%). Twenty patients (87%) received erythropoietin, 9 (39.1%) had red cell transfusion, and 2 (8.7%) had granulocyte stimulating agents. Antiviral therapy discontinuation was required in 8 (34.7%) patients for virological non-response (n=5), virological relapse (n=2) and depression (n=1).
conclusionsPeg-IFNα/ribavirin/protease inhibitor combination seems highly effective in HCV-MC. Such therapeutic regimen should be administered cautiously considering the high rate of side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.